Concepedia

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

Kim Papp, Richard G. Langley, Mark Lebwohl, Gerald G. Krueger, Philippe Szapary, Newman Yeilding, Cynthia Guzzo, Ming-Chun Hsu, Yuhua Wang, Shu Li,

The Lancet · 2008 · 1.4K citations · 15 references

DOI

Concepts

References

15

Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use

A.Y. Finlay, Ghazala Khan · Clinical and Experimental Dermatology · 1994 · 5.5K citations

, , +8

Severe Psoriasis – Oral Therapy with a New Retinoid

T Fredriksson, U. Pettersson · Dermatologica · 2009 · 2.7K citations

, , +11

Sequential Treatment Assignment with Balancing for Prognostic Factors in the Controlled Clinical Trial

Stuart Pocock, Richard Simon · Biometrics · 1975 · 2.4K citations

, , +12

Risk of Myocardial Infarction in Patients With Psoriasis

Joel M. Gelfand, Andrea L. Neimann, Daniel B. Shin et al. · JAMA · 2006 · 1.9K citations

, , +15

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

Craig L. Leonardi, Alexa B. Kimball, Kim Papp et al. · The Lancet · 2008 · 1.9K citations

, , +15